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ACRONYMS
ANC		

antenatal care

ARV		

antiretroviral

CBR		

Population Council’s Center for Biomedical Research

EC		

emergency contraception

FC		

female condom

FP		

family planning

GRADE		

Grading of Recommendations Assessment, Development, and Evaluation

MCH		

maternal and child health

OR		

operations research

PHC		

primary health care

PICOT		

Population, Intervention, Comparison or Control, Outcome, and Time

PMTCT		

prevention of mother-to-child transmission

PrEP		

pre-exposure prophylaxis

RH		

reproductive health

USAID		

U.S. Agency for International Development

VCT		

voluntary counseling and testing

WHO		

World Health Organization

BACKGROUND AND RATIONALE
The HIV prevention research field has yielded a number of important new approaches during
the last several years, including medical male circumcision, oral pre-exposure prophylaxis
(PrEP), and treatment as prevention. Together with male and female condoms, prevention
of mother-to-child transmission (PMTCT), and antiretroviral (ARV) treatment, these interventions have the potential to help decrease the rate of new HIV infections and begin to curb the
epidemic overall. At the same time, the need for women-centered products remains. Clinical
effectiveness trials are under way for 1 percent tenofovir gel and the dapivirine ring, and
research on other ARV-containing gels and rings continues. Given the urgent need for these
products, the groundwork for introduction and rollout is being laid in parallel with clinical
research.
The Population Council, in collaboration with U.S. Agency for International Development
(USAID) and other partners, is engaged in a program of research and action to prepare for
the successful introduction of women-centered ARV-based HIV prevention methods. Following
the results of the CAPRISA 004 trial, which demonstrated that tenofovir gel reduced the risk
of HIV infection, USAID outlined a “Shared Vision”1 for access to microbicides that included
development of an operations research agenda as one of its elements.
Developing such an operations research (OR) agenda to prepare for the introduction of a
new product is an important but often overlooked step. Clinical trials assess the safety and
efficacy of medical interventions in tightly controlled settings; as such, they are not designed
to address critical questions related to service provision under routine circumstances. Operations research generally identifies health system and service delivery issues and tests
programmatic options for program managers and policymakers to consider when designing
approaches to introduce or expand access to a product.
To help shape this agenda, the Population Council drew on its long experience and expertise
in microbicide product development and testing, as well as operations research in developing countries for family planning, reproductive health, and HIV/AIDS, all potential systems
for microbicide delivery.2 Given that numerous other efforts are under way to address the
delivery of oral Truvada for PrEP, and that clinical research on rectal microbicides is in earlier
phases, this meeting focused specifically on gels and rings for vaginal use. While recognizing
the significance of other biomedical interventions (such as male circumcision, oral PrEP, and
treatment as prevention), the need for women-centered products remains critical. Making
these products available requires a wide range of activities in areas including clinical testing,
regulatory strategy, licensure, manufacturing, and financing. While all are key to delivering
products, this meeting focused specifically on an operations research agenda for gels and
rings.

USAID Proposal for a Shared Vision and Strategic Plan for Microbicide Introduction, May 24, 2011. http://transition.usaid.gov/our_work/global_health/aids/TechAreas/research/strategic_plan_microbicide_introduction.pdf.
1

See, for example, Fisher, Andrew A. and James R. Foreit. 2002. Designing HIV/AIDS Intervention Studies: An
Operations Research Handbook. New York: Population Council.
2
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MEETING PARTICIPANTS, AGENDA, FORMAT
The two-day meeting (17–18 June 2012) drew together nearly 40 diverse participants, with
approximately half coming from a number of countries in Africa or India. Participants’ expertise spanned operations research, microbicide clinical research and product development,
AIDS care and services, policy and program implementation, and social and behavioral
research. Council staff drew on their experience and a review of key documents and tools
(see Appendix 1) to develop a list of potential operations research questions across a number
of domains (see Appendix 2). Some of these questions are discussed more fully later in the
report. To engage meeting participants with the issues and get an initial sense of priority and
timing, the questions were sent to participants prior to the meeting for their feedback.
Given the complexity and rapid evolution of the ARV-prevention landscape and the product
pipeline, the first part of the meeting was devoted to reviewing recent results and developments in clinical testing, product development, acceptability, and regulatory review. Speakers
also offered insights and analysis on lessons from other product introduction efforts, outlined
the Population, Intervention, Comparison or Control, Outcome, and Time (PICOT) and Grading
of Recommendations Assessment, Development, and Evaluation (GRADE) processes used by
the World Health Organization (WHO) in weighing evidence to develop guidance, and offered
a primer on operations research approaches, including highlighting the types of questions
that OR can—and cannot—address.
During lively discussion and debate, meeting participants worked to identify priority OR
issues and began to outline how studies could be designed to address these questions.
These discussions took place in the larger group as well as in breakout sessions where small
groups identified key issues for the different technologies (gels and rings) and then outlined
approaches to operations research on several priority topics. This report highlights the main
themes identified in the presentations and discussions, and outlines ideas generated for
priority research topics and approaches.

WOMEN AND HIV PREVENTION: WHAT WORKS?
The meeting began with an overview of biomedical, behavioral, and structural interventions
currently available to women to reduce their risk of HIV infection. A comprehensive review
of evidence on “what works for women” (www.whatworksforwomen.org) undertaken by the
Futures Group notes a number of strategies to help women prevent HIV, including male and
female condom use, reducing the number of partners, and treatment for sexually transmitted
infections. Treatment as prevention also offers a promising new approach, though questions
remain about its implementation in resource-limited settings.3 The review also notes that preBased on recent research and resulting regulatory and policy guidance, pre-exposure prophylaxis may also provide an important prevention strategy for women. However, it is not yet included in www.whatworksforwomen.org.
3
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vention efforts for married women have been neglected, although married women may be at
increased risk of HIV. The review suggests that efforts be increased to meet women’s reproductive health needs, including increasing condom use, sexuality education and communication, especially among young people. Overall, it highlights the limitations of approaches
currently available and the need for more biomedical and structural tools, options, and
approaches to empower women to help prevent HIV. The review underscores the importance
of the consultation as part of efforts to develop and make rapidly available gels, rings, and
other new technologies for women.

LESSONS FROM OTHER HEALTH TECHNOLOGIES
Experience with introducing other health technologies provides a number of useful lessons
that can be applied to ARV-based prevention for women, although no existing product offers
a precise model. A number of lessons can be drawn from emergency contraception, contraceptive vaginal rings, the female condom, HPV vaccine, and HIV treatment. Overall, across
time, setting, and products, women’s overarching questions about new reproductive health
technologies, including those for HIV prevention, are relatively straightforward and center on
whether a product works, whether it causes harm (to the woman, her partner, or her baby),
whether it will jeopardize future fertility, and whether it will disrupt her relationship with her
partner.
Although women’s unmet need for modern contraception may appear to be attributable to
problems with access, a 2011 analysis showed several other issues as central: concerns
about health or side effects, opposition from the woman or her partner, and infrequent sex.4
This may suggest that coitally dependent products could fill an important niche, in contrast
with concerns that women will struggle to use such products consistently.
Emergency contraception (EC) shares a number of attributes with peri-coital gel use: both
are user initiated, time sensitive, and require information and understanding to be used
effectively. Women use EC even when other highly effective contraceptive products are
available, and express interest in peri-coital methods. Although emergency contraception
continues to be stigmatized in many settings, women still want it and generally prefer to have
on-demand pharmacy access. Multiple brands are on the market in different settings, suggesting both a continued “unmet need” and its commercial viability. Finally, while making EC
available without a prescription has expanded access, such availability does have its downsides, making it difficult to monitor product safety and quality and to provide counseling. It
also requires that women have funds available to purchase the product.
Contraceptive vaginal rings can offer some clear lessons and parallels for ARV-containing
rings. Protocols and duration of use vary among rings currently on the market which include
Darroch, Jacqueline E., Guilda Sedgh, and Haley Ball. 2011. Contraceptive Technologies: Responding to Women’s
Needs. New York: Guttmacher Institute.
4
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monthly and three-month rings. While such rings do not require action daily or at the time of
sex, they do require user effort. Experience with rings dates back decades, but most data is
from the US and Europe and there is a need both to mine and perhaps generate more data
on women’s experience with rings in a variety of settings. One important issue is expulsion
and slippage among women with different reproductive histories, which needs to be documented and proactively addressed with users.
The female condom (FC) is often cited as an important example for microbicide introduction
and there are clear parallels and lessons from this coitally related, user- dependent, vaginally
inserted method. The female condom was subject to strong provider and policymaker bias,
which, coupled with relatively high production costs, resulted in a cycle of low demand and
high cost. Like the gels and rings being developed for vaginal use, the FC is not a perfect
product. Many women can and do use the FC, however, especially if they are supported as
they become accustomed to and experienced with it; user education includes communication
and negotiation skills and information on sexuality and anatomy. Consistent use, while optimal, is difficult for many women to achieve, suggesting that HIV prevention products should
ideally be provided together as a range of options so users can choose and switch among
strategies to maximize their overall protection.
Finally, efforts to introduce ARV-based gels and rings should be informed by the extraordinary global efforts to roll out HIV treatment and care. Maintaining adherence for any health
intervention over time is challenging, and it is important that program approaches acknowledge that incomplete adherence is normative for both treatment and prevention while at
the same time developing, testing, and implementing approaches to bolster adherence. HIV
testing is the gateway for use of ARV-based prevention and for antiretroviral therapy, and both
approaches will require medical monitoring. All of the issues outlined above have implications
for determining which service-delivery settings will be feasible, the periodicity of testing and
resupply, what types of provider will be permitted to deliver the service, and scalability.
These examples and others underscore that product introduction efforts need to demonstrate that health systems and providers have the capacity to deliver the product safely and
effectively; that the product and program are affordable and acceptable to users, programs,
and funders; and that key (and potentially diverse) user groups can access and use the
product as well as the program that delivers it. A vision needs to be presented for how a
given product (such as tenofovir gel or the dapivirine ring) fits into the overall HIV prevention
landscape globally and in specific settings, and satisfactory answers must be developed to
address any concerns.
Drawing on a number of analyses, including a previous Council meeting and publication on
this topic,5 the relevant lessons and insights that can be applied to microbicide introduction
are relatively clear and can inform operations research and program design for delivering
ARV-based gels and rings without a great deal of additional analysis. Incorporating these
lessons into program design will require vision, commitment, and investment.
Brady, Martha, and Elizabeth McGrory. 2007. “Insights and evidence from product introduction: Lessons for
microbicides,” Day of Dialogue. New York: Population Council.
5
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WHERE ARE WE WITH MICROBICIDES?
Product pipeline and lead products
A review of the microbicide pipeline provided background information on the status of various
product leads, focusing on 1 percent tenofovir gel and the dapivirine ring, the products furthest along in development. FACTS 001, a safety and effectiveness trial of 1 percent tenofovir
gel, is currently under way in South Africa with results expected in 2014. Two effectiveness trials of 1 percent tenofovir gel have been conducted, with one showing a 39 percent reduction
in risk of HIV acquisition (CAPRISA 004) and the other showing no effect (VOICE). A different
formulation of 1 percent tenofovir gel is also being developed for rectal use. Two safety and
effectiveness trials of the dapivirine ring, a sustained-release device, are expected to report
results in 2015 (ASPIRE and the Ring Study). For both of these lead products, additional studies will provide data on safety during pregnancy and when breastfeeding, use in adolescents,
drug interactions, manufacturing, and other issues necessary for licensure. The Population
Council, CONRAD, and other groups continue research and development on other product
leads, some of which are also multipurpose prevention technologies designed to also act as
contraceptives.
AVAC, September 2012

HIV Prevention Options Timeline * **
2010
1

2

3

2011
4

1

2

2012

3

4

1

2

3

2013
4

1

2

3

2014
4

1

Oral TDF

2005 Bangkok Tenofovir Study/CDC 4370
2008

Partners PrEP

2009

VOICE/MTN 003

2

3

2015
4

1

2

3

2016
4

TIMELINE LEGEND

Partners PrEP (no placebo)

Oral TDF/FTC

2

3

4

Oral TDF
Oral TDF/FTC

Positive efficacy result

TFV gel
Arm stopped

2007 TDF2/CDC 4940
2007 iPrEx

1

TDF2 Open-Label Extension

Regulatory submission/filing

iPrEx Open-Label Extension (OLE)

2009 FEM-PrEP

Rectal TFV gel

Additional demonstration projects &
intermittent PrEP studies

DPV ring

Planned

TMC278 LA Injectable

Final results pending

DNA/Ad5
Pox-Protein

US FDA filing and decision
CAPRISA 008

2009 VOICE/MTN 003

Earliest regulatory
submission

FACTS 001
FACTS 002 (adolescents)

Rectal
TFV gel

TFV gel

2007 CAPRISA 004

MTN 017

DPV
Ring

ASPIRE/MTN 020

TMC 278
LA Inject.
DNA/Ad5
Pox-Protein

Earliest
regulatory
submission

The Ring Study/IPM 027

Possible TMC278 LA Injectable
2009

HVTN 505
South Africa Licensure

RV 144
2004

Various Phase I/II preliminary and bridging studies

.

South Africa Research
Thai Licensure

.

* Trial end-dates are estimates; due to the nature of clinical trials the actual dates may change. For full trial details, see www.avac.org/trials.
** Not all trials included are effectiveness trials. Trials included on this list are mainly phase II/IIb, III/IIIb and IV trials.

Updated timeline available at www.avac.org/ht/a/GetDocumentAction/i/46212

This timeline suggests that ARV-based gels and rings will be introduced into an increasingly dynamic and complex
environment of prevention approaches with implications for service delivery, user education and action, and investment.
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Acceptability and use
Ongoing product development for gels and rings for HIV prevention has been accompanied
and informed by acceptability research at all phases of preclinical and clinical development.
This research has been conducted within and outside of clinical trials. Acceptability research
to date indicates that overall women are quite positive about the products being tested and
that although different women have different preferences, all delivery forms are acceptable.
Some women are interested in using a product without telling their partner(s), although
involving male partners is important for some women and in some settings. Cultural norms
including those for “tight” or “dry” sex have not negatively affected acceptability, and in fact
many women in trials (and their partners) report that microbicide gels make sex more comfortable and pleasurable. Acceptability needs to be assessed and addressed for providers,
policymakers, and other key decisionmakers as well as users. Important dimensions for
acceptability go beyond basic product characteristics and include issues like storage and
disposal.
Clinical trials offer a critical opportunity to learn about acceptability, and rich datasets exist
from completed clinical trials as well as those being generated in ongoing trials. Additional
information may be available from research and from the introduction of related technologies
like contraceptive vaginal rings. In many cases, these data have not been thoroughly analyzed or applied, and they should be exploited to frame further studies and inform any future
introduction efforts. At the same time, it is unclear how findings from trials will translate to
ongoing use in routine service settings, so further research may be needed to assess dimensions of acceptability as products are phased into wider use.

OPERATIONS RESEARCH: WHAT IT CAN AND CANNOT DO
A review of operations research underscored that while there is some fluidity in definitions,
parameters, and terminology, in general OR looks at the health system as the unit of analysis and seeks to measure outcome indicators for service delivery that are meaningful for
program design, budgeting, and management. OR generates evidence to guide policy, programming, and budgeting for service delivery, and different types of research are needed to
generate different types of evidence. OR produces evidence on issues like the delivery attributes for the provider, system, and user; system requirements and functioning for effective
service delivery; parameters for policy support and delivery; and commodities logistics, cost,
and prices. As such it complements research that is biomedical, clinical, or oriented to user
behavior and acceptability. At the same time, not all problems or questions related to service
implementation need to be addressed by research-based evidence, and it is important to
ensure that research approaches match the questions they are seeking to address.
Operations research studies need to clearly define and understand potential audiences and
how they would use the evidence generated, as well as the systems adjustments needed for
introducing and implementing any operational changes indicated by the OR findings. Specific
questions can be addressed through nested studies and multisite studies, as the OR itself
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should not be disaggregated into too many smaller, discrete studies. Developing OR should
involve the end users of the research (for example, the Ministry or system responsible for
implementation) and should include both plans and budget for extended actions beyond the
study period to support institutionalization and scale-up of activities indicated by research
evidence. Given this, the cycle for an OR project can often stretch for several years—time to
understand the evidence needed and design the OR study, prospectively conduct an assessment or evaluation of a service-delivery intervention, and then time to support the health
system with institutionalization and scale-up of the organizational changes suggested by the
OR findings.

WHO GUIDANCE
WHO guidance will be critical to shaping country policy in many settings and is an essential
step toward inclusion on WHO’s Model List of Essential Medicines and for launching the
prequalification process. WHO is planning to establish a Guideline Development Group by
the end of 2012, with a target of having guidance ready for publication soon after the first
licensure decision on 1 percent tenofovir gel. The detail and specificity of guidance that can
be issued depends on the extent of evidence available to inform that guidance. WHO anticipates that the Guideline Development Group will agree on a limited number of critical questions that need to be answered in order to issue initial policy guidance. These questions can
also be used to inform priorities for operations and implementation research that needs to be
completed in time for the results to be reflected in the guidance.
WHO uses the Grading of Recommendations Assessment, Development, and Evaluation
(GRADE) approach to review and weigh the evidence on which the guidance is based. It rates
the quality of evidence on a number of parameters (study design, risk of bias, completeness
of follow-up, imprecision, inconsistency, indirectness, and the magnitude of the effect), and
grades the strength of recommendations (high, moderate, low, very low). In this system, evidence from randomized controlled trials is initially rated higher than evidence from observational studies, but the factors mentioned above are used to increase or decrease the quality
of evidence scores. This approach, initially developed to assess clinical evidence, presents
challenges with respect to incorporating evidence from OR. Randomized controlled trials
are generally inappropriate designs for operations research for reasons that include: the
practical and ethical challenges with random assignment, large sample sizes, and controlled
implementation; and experimental conditions that are unlike routine service settings. But OR
has greater external validity and addresses key policy questions necessary to inform guidance and country policies. It is important to note that WHO normative guidance addresses
policy questions, such as whether a particular product or policy should be introduced into
programs, and if so how, based on a wider assessment of risks, costs, and opportunity costs.
This is distinct from the role of national regulatory authorities which assess safety and efficacy of a new product in order to grant market authorization and thus allow the product to be
marketed within their jurisdiction.
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The GRADE “PICOT” (Population, Intervention, Comparison or Control, Outcome, and Time)
approach is designed to clearly define the questions for which evidence is systematically
compiled and assessed. Policy questions to be addressed through the PICOT approach often
have very limited information to support a recommendation, particularly for new products
for which there is no, or limited, programmatic experience. But operations research that
addresses questions on how to deliver a gel or ring safely and consistently, user preferences
for different HIV prevention products, and identifying niche(s) where the product will be used
effectively and have the greatest acceptability and impact would be very valuable to inform
guidance. The framework and approaches WHO is currently developing for oral PrEP demonstration projects may be useful for framing OR on gels and rings, and staff at WHO and others
interested in microbicide OR and implementation should stay apprised of these efforts.
Experience with developing operations research and policy guidance with oral PrEP will also
inform research on introduction of gels and rings.

PRIORITY TOPICS, SELECTED QUESTIONS,
AND EXPERT FEEDBACK
Participants identified a number of priority topics for operations research both prior to and
during the consultation. Much of the discussion focused on models for service delivery,
timing, and the use of proxy products, approaches to conveying partial effectiveness, and
bolstering adherence.

Sample questions for expert review
Drawing on the Council’s expertise and a review of key tools, reports, and literature (see
Appendix 1), Council staff developed a number of questions related to operations research
across a range of domains (see boxes in this section for select questions and Appendix 2 for
the full survey):
•
•
•
•
•

Service delivery models
Providers
HIV testing and retesting
Potential resistance
Adherence

•
•
•
•

Vaginal ring–specific issues
Vaginal gel–specific issues
User perspectives and education
Program costs

These questions were sent to participants prior to the meeting, and participants were
asked to rate the questions by level of importance (high, medium, low) and to indicate when
research could or should be initiated to address the issue (actionable now, or after a product is approved and available). Responses received were compiled prior to the meeting and
presented to meeting participants for an overall sense of priorities and to help jump-start the
discussion and debate.

8 ■ Shaping the OR agenda for ARV-based prevention products for women: Gels and rings

Most items were rated “high” to “medium”
priority, with some ranked “high” but not
actionable now. With regard to timing, for
many questions it was difficult to make
clear distinctions as to when a question
could and should best be explored. For
a number of topics, research conducted
while clinical trials are ongoing could yield
important findings and insights, which
could then inform additional work or
research in more routine service settings.
The time between demonstration of clinical efficacy and formal approval and/or
widespread availability may be particularly
fruitful for operations research to inform
program design and implementation.

Priority areas

Select OR Questions
Service Delivery Models, Programs,
Services
• What service model(s) or package is most
effective for reaching key populations? Under
what conditions? Which populations?
• Which program entry points would be most
effective to deliver gel/ring (e.g., RH/FP, ANC,
counseling and testing services, primary
health care, school health, private sector,
etc.)?
Providers: Type, Level, Training
• What cadre(s) (nurse, clinical officer, health
worker) of providers is needed to ensure
appropriate counseling, provision, testing,
resupply, and follow-up?
• What are providers’ attitudes and beliefs
around ARV-based prevention in general and
gel/ring in particular? How can these be influenced to facilitate successful introduction?

Priority questions focused primarily on
HIV Testing and Retesting
identifying appropriate service-delivery
• What are the implications of the need for perimodels and approaches for reaching
odic HIV testing on product acceptability and
different potential user groups, including
uptake among users, providers, and health
the types of program entry points (such
systems?
as reproductive health, antenatal care,
•
What are the acceptability and feasibility of
HIV counseling and testing, school-based,
different HIV screening and testing approaches
etc.). Other priorities concerned related
to: Clients? Providers? The service site? The
service issues such as the level of prohealth system overall?
vider who could safely and appropriately
Potential Resistance (understanding, minimizdeliver ARV-based prevention products,
ing, managing)
the kind of medical monitoring that would
• How can potential drug resistance be deterbe required, and the feasibility and need
mined, minimized, and managed in routine
for monitoring potential resistance. It
services?
will also be important to understand the
• What is the realistic risk of resistance with use
implications of periodic HIV testing (for
of ARV-containing gels and rings?
screening for initiating product use as well
as for ongoing monitoring of HIV status)
on acceptability and uptake among users,
providers, and the health system. Recognizing the important role that providers play in influencing policy as well as services, provider knowledge and attitudes were also seen as important. Whereas some issues related to providers can be addressed through research, work in
this area will also involve education and training.
Participants also identified priorities related to product adherence as well as specific topics
relevant to gel and to rings. It has been challenging to maintain and to measure adherence
in microbicide trials, and developing and testing approaches to bolstering adherence out-

Consultation report ■ 9

Select OR Questions (con’t)
Adherence: Optimizing and Measuring
• What strategies or combination of strategies
(counseling, communications, mobile technologies) are effective for supporting and bolstering adherence among users?
• What are feasible approaches to measuring
or assessing adherence under routine service
conditions?
Vaginal Ring–Specific Issues
• How can ring service provision be proactive in
supporting women’s use of the ring, including helping women understand and manage
potential expulsions?
• Given that the vaginal ring is not coitally
dependent and does not require daily action,
what are the implications for adherence, use,
user satisfaction?
Vaginal Gel–Specific Issues
• How will the amount of gel provided to users
at each visit be determined? Will initial
and resupply visits take place at the same
location?
• What are the storage implications for gel at the
service-delivery site? For the user? For logistics
and supply systems?
User Perspectives and Education
• What do women know about ARV-based prevention? What are their views about the gel/
ring? What are their partners’ views?
• How can the gel/ring’s partial effectiveness
best be communicated to users?

side of trials was seen as a clear priority,
though the timing is uncertain. Overall,
there is less information from trials on
the ring than gel, and technology-specific
priorities focused on supporting women
to understand and use the ring, as well
as the implications of a sustained-release
method for adherence, use, and user
satisfaction. For gel, the priorities were
somewhat more instrumental, such as
what amount to provide at each visit, storage for users and the health system, and
the implications of switching from prefilled
to user-filled applicators.
Priorities for user perspectives and education centered around how best to communicate partial effectiveness, and specific
counseling requirements for initial adoption and ongoing use/resupply of gel and
rings. Finally, the cost implications of different service models, as well as who will
pay for the product and programs, were
seen by some as a priority. Those issues
that surfaced throughout the meeting are
discussed in more detail in the following
sections.
Populations, service types, and service
settings: Weaving it together

Determining which service-delivery settings would be most appropriate and
Program Costs
feasible to reach different user groups—
• What are the anticipated (or likely) product,
the heart of operations research—was a
service, and program costs? Who is expected
main theme throughout the consultation.
to pay for these costs?
Priority user groups would be determined
• What implications do different program models
by the specific epidemic in a given setand scenarios have for cost?
ting, as would available services on which
to build. For more specific discussions,
participants broke into two groups to try
to define OR studies and begin to map out study designs using the PICOT framework. With
some differences, both groups proposed and worked through similar broad study outlines to
explore different dimensions of feasibility, acceptability, cost, and reach of building on existing services to deliver the gel and/or ring to specific user groups.
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• Population: Relevant population groups would be determined by the nature of the
epidemic in a given setting, and the small groups discussed several possible populations for initial OR studies. For example, married women in Kenya and young women in
South Africa were both seen to be likely user groups for ARV-based prevention technologies. Most participants felt that initial OR studies could and should be focused
in the communities that hosted gel or ring trials. While located in trial communities,
OR studies should not be limited to trial participants and, depending on their design,
should generally not take place in trial clinics.
• Intervention: Priority interventions would focus on different packages of services that
include HIV testing and retesting with product supply and resupply (for either ring or
gel). These services would be delivered in different settings such as family planning/
reproductive health services, HIV testing services, and possibly school-based service
points.
• Comparison: The studies could be designed to compare different service intervals (for
example providing the same service every three months versus every six months) or
different service types.
• Outcome: Outcomes could include retention in services, adherence, acceptability,
and/or cost. One group discussed the emergence of drug-resistant virus as a research
priority. Some aspects of resistance could be explored through OR while others would
call for clinical research. Priority “nested” studies to investigate specific issues within
the context of broader OR efforts could include models for testing, counseling, and
information provision, and challenges to logistics or supply-chain management.
• Time: The proposed timeframe varied from one to two years, depending on the specific
intervention. Some participants argued for a timeframe longer than one year given
that retention in microbicide gel trials dropped off after a year.
Timing: When to initiate what types of research
It can be difficult to clearly distinguish when operations research is most appropriate and
fruitful for many issues. Some topics—for example, participants’ understanding of partial
effectiveness—may lend themselves to research in the context of clinical trials, either as
a formal part of the trial or an ancillary study. However, findings from studies that employ
the participants, clinic staff, and resources from trials may have limited relevance for more
routine service settings. Other priority issues, such as testing different approaches to bolstering adherence, may not be possible within randomized controlled clinical trials where
service interventions need to remain consistent across comparison groups. Studies under
more routine service settings may not be feasible for products that are not yet licensed in a
country, though this may be possible in some settings under a research designation. Ideally
many issues could be explored in clinical trials and ancillary studies, and then further refined
through operations research in pre-introductory and early rollout phases. However, resource
constraints may limit such a phased approach. The tension between needing information
relevant to implementation in routine service settings, and the limitations on conducting
research in such settings with products that are not yet licensed, will remain.

Consultation report ■ 11

Proxy products: What can we learn from proxies and how can this knowledge be applied?
Most OR is conducted with available products, and the discussion returned repeatedly to
the challenging issue of conducting operations research for products under development.
Both tenofovir gel and the dapivirine ring will be strictly controlled until they are licensed
and approved by national regulatory authorities. While it may be possible to conduct some
studies with proxy products, there was considerable debate about the value of research with
proxy products (for example, the contraceptive vaginal ring or sexual lubricants) for informing service design, logistics, and other aspects of delivering ARV-containing microbicide
products. While some participants felt this approach would yield valuable information about
product introduction and delivery, others noted that the differences—for example in service
components (such as HIV testing) and motivation of users and providers (to use sexual lubricants compared with tenofovir gel for HIV prevention)—would be so significant that it would
be difficult to garner useful lessons for microbicide introduction. Given the publicity around
tenofovir gel in South Africa, for example, it could even be misunderstood that the lubricant is
tenofovir gel, which could cause confusion and might even put women at risk. This issue was
not clearly resolved; proxy research may be useful under specific conditions and in different
settings, but the implications need careful consideration.
Partial effectiveness: What and how to convey?
A great deal of discussion surrounded the importance and complexity of conveying partial
effectiveness to users and policymakers. Generally, participants agreed that shifting both
the language and concept from “prevention” to “risk reduction” is important as it may allow
and indeed force a rethinking of the concept of “partial effectiveness” and how it can be
conveyed in a more affirmative and accurate manner. Such research could draw on other
examples of interventions that reduce but do not eliminate risk (such as immunization or
seat belts). A useful step would be to review how partial effectiveness has been explained
(and understood) in trials to date, and use this information to develop additional research
on partial effectiveness, including context specific terminology and concepts, outside of trial
populations.
Gels and rings: Shared contexts, unique products
Recognizing the different product attributes and use dynamics between gels and rings,
participants broke into two groups to discuss and identify priority research particular to each
technology. Given that a number of candidate microbicide gels have been developed and
tested in Phase 3 trials, much more data and experience with gels exists. Much of the discussion focused on contextual issues: identifying settings, populations, and individuals who are
at risk and thus could benefit most from the gel; how to ensure that the gel is not stigmatized
through association with risk groups or behaviors; the possibility of positioning the gel for
use in intimate partnerships; and innovative approaches to balancing the need for monitoring with ease of access and ensuring women have an adequate supply including the use of
smart cards, SMS, or other electronic approaches. Priority topics for rings include whether
women would choose a ring if they were not having sex regularly; the reasons women remove
rings, and what is done with the ring when it is taken out; and how to convey the impact of
imperfect use on the ring’s effectiveness.
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Bolstering adherence: How to do it? And then, how to measure it?
Supporting and measuring adherence has been a significant challenge in clinical trials, and it
is not known whether adherence will be more or less difficult in ongoing use of proven products. While a great deal of thought and effort has gone into improving approaches to measuring adherence, relatively less has been invested in evaluating counseling and strategies for
improving adherence. Several discussions centered on approaches to bolstering adherence
and whether different approaches could be compared in the context of a clinical trial as a
nested study. Given the complexity of implementing trials and keeping variation to a minimum, such adherence studies may not be feasible until bridging or pre-introduction studies.
One participant noted that specific strategies for improving adherence efforts in trials have
not been rigorously evaluated and that doing so may be a productive initial step.
Other cross-cutting issues: Developing champions, civil society engagement
During the consultation’s lively and wide-ranging discussions, a number of important issues
surfaced that, while critically important, do not lend themselves to operations research per
se. For example, discussion returned repeatedly to the best ways to engage providers, who
need to be informed about research on gels and rings and brought on board as champions.
Similarly, community and advocacy groups offer important perspectives to inform preparation
for product introduction and could press governments and donors to invest in new prevention approaches for women. However, appropriately timing such professional and community engagement needs to balance ensuring that key constituencies are informed, and feel
informed, without potentially raising expectations too soon and without a clear plan of action.
Defining the market, estimating demand, and understanding market segmentation
While not explicitly discussed during the operations research consultation, product developers working to make tenofovir gel available outlined several critical issues related to estimating and defining the market and reaching users with the product. The coalition of groups that
has developed and tested tenofovir gel has come primarily from the public and philanthropic
sectors driven by a public health imperative. As the product moves through advanced clinical
testing, these efforts are shifting to estimating and defining the market for tenofovir gel to
inform manufacturing, investment, and pricing scenarios. Such efforts concern identifying
potential user groups in different contexts and then more precisely estimating the uptake and
use of the gel to balance building demand with ensuring adequate supply to meet that as yet
undefined demand. At the same time, as a product that will likely be subsidized and provided
chiefly through the public sector, efforts to provide tenofovir gel will depend on programs
developed, funded, and implemented through the public health sector, and interest and commitment to this needs to be understood and to the extent possible, quantified.
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LOOKING AHEAD AND MOVING FORWARD
Developing an operations research agenda takes time and is challenging without defined
products, settings, and populations. The OR consultation engaged its diverse participants in
grappling with how best to define and prioritize research related to delivering ARV-containing
gels and rings for women. The process of developing an OR agenda will continue as clinical
data continue to emerge on ARV-containing gels and rings. Useful data and lessons will also
emerge from the PrEP demonstration projects now being designed and implemented, and
it will be important to ensure that some of those projects are developed with an eye to also
informing introduction of gels and rings.
Ultimately, the OR agenda for new women-centered prevention will need to be defined by
key stakeholders within the framework of specific health systems and epidemics. Given the
timeframe for ongoing clinical research and new approaches like medical male circumcision
and PrEP that have emerged in the last several years, ARV-containing gels and rings will be
introduced as an element of combination prevention. As such, new products will need to be
examined and understood within the range of prevention options available. While developing
and implementing an OR agenda is a crucial part of preparing for new product introduction,
ultimately programs will need to move forward without every question answered. This is and
will continue to be a challenging and dynamic process.
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APPENDIX 1
REPORTS AND ARTICLES REVIEWED FOR THE
CONSULTATION
Document

Author/Organization

Year

Development and coordination of programmatic
research on tenofovir gel

WHO, UNAIDS

2011

Report of a consultation: Preparing for pre-exposure
prophylaxis (PrEP) results: From research to
implementation

WHO

2009

WHO, UNAIDS

2008

C. Celum

201112

M. Brady and E. McGrory
Population Council

2007

Planning for PrEP

Kim et al.

2009

Report published in Journal of IAS 2010; 13:24.
http://www.jiasociety.org/content/13/1/24

Georgetown University,
Imperial College, Gates
Foundation

Microbicide access forum meeting

IPM, USAID, WHO

2007

Microbicide access forum meeting report

IPM, Population Council,
USAID, WHO

2008

Microbicide access forum meeting report

IPM, USAID, WHO

2009

Mind the gap: Summary of microbicide access forum

IPM, WHO, UNAIDS, AVAC

2011

http://whqlibdoc.who.int/publications/2010/9789241599795_eng.pdf
Next steps with 1% tenofovir gel
http://www.who.int/reproductivehealth/topics/rtis/
WHO_UNAIDS_Next_steps_tenofovir_gel_Ex_report.pdf
HIV PrEP: New data and potential use
Topics in Antiviral Medicine
December 2011/January 2012; (19)5.
Insights and evidence from product introduction:
Lessons for microbicides
Day of dialogue meeting report
http://www.popcouncil.org/pdfs/DoDMicrobicides.pdf
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Document

Author/Organization

Date

Stakeholder meeting on pre-exposure prophylaxis

WHO, UNAIDS, Imperial
College London, London
School of Hygiene and
Tropical Medicine, and
Georgetown University

2011

Packaging PrEP to prevent HIV: An integrated
framework to plan for pre-exposure prophylaxis
implementation in clinical practice

K. Underhill et al.

2010

A. Fisher et al.
Population Council

2002

J. Gay et al.
Open Society Institute

2010

S.A. Golub, D. Operario
and P.M. Gorbach

2010

A. Coly and P. Gorbach

2008

Journal of Acquired Immune Deficiency Syndromes 2010;
55(1):8-13.
Designing HIV/AIDS Intervention Studies:
An Operations Research Handbook
http://www.popcouncil.org/pdfs/horizons/orhivaidshndbk.pdf
What works for women and girls: evidence for HIV/
AIDS interventions
www.whatworksforwomen.org
Pre-exposure prophylaxis state of the science:
Empirical analogies for research and implementation
Current HIV/AIDS Reports 2010; 7(4): 201–209.
http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC2938422/?tool=pubmed
Microbicide acceptability research: recent findings and
evolution across phases of product development
Current Opinion in HIV and AIDS 2008; 3(5): 581–586.
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APPENDIX 2
QUESTIONS FOR EXPERT REVIEW
These pages contain the full set of questions sent to participants prior to the meeting for
review and prioritization. Council staff reviewed and compiled the feedback to serve as a
starting point for the discussions and deliberations at the consultation.
Questions

Timing Priority
(1, 2)

I.

Comments

(H, M, L)

Service Delivery Models, Programs, Services

1. What service model(s) or package is most effective for
reaching key populations? Under what conditions? Which
populations?
2. Which program entry points would be most effective to
deliver gel/ring (e.g., RH/FP, ANC, counseling and testing
services, primary health care, school health, private sector,
etc.)?
3. What are the resource requirements of different program
delivery approaches?
4. How do counseling needs for gel/ring fit within counseling
needs for other services?
5. How does providing the new product (gel or ring) affect existing services in terms of client flow, operations, staffing, etc.?
6. What are the implications of the need for medical monitoring
for provider and service type?
II. Providers: Type, Level, Training
1. What cadre(s) (nurse, clinical officer, health worker) of providers are needed to ensure appropriate counseling, provision,
testing, resupply and follow-up?
2. What are providers’ attitudes and beliefs around ARV-based
prevention in general and gel/ring in particular? How can
these be influenced to facilitate successful introduction?
3. What is the lowest level of health care provider suitable to
ARV-based gel or ring implementation?
4. What is the role of supervision in ensuring the fidelity of information/messages and the quality of service provision?
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Questions

Timing Priority
(1, 2)

III. HIV Testing and Retesting
1. What are the implications of the need for periodic HIV testing
on product acceptability and uptake among users, providers,
and health systems?
2. What are the acceptability and feasibility of different HIV
screening and testing approaches to: Clients? Providers? The
service site? The health system overall?
3. What education strategies are most effective in conveying to
users the importance of regular retesting for HIV? Does this
correlate with actual retesting?
4. What are the implications of HIV testing and retesting for
cost and cost effectiveness?
IV. Potential Resistance (understanding, minimizing,
managing)
1. How can potential drug resistance be determined, minimized, and managed in routine services?
2. What is the realistic risk of resistance with use of ARVcontaining gels and rings?
3. What is the feasibility of monitoring resistance?
V.

Adherence: Optimizing and Measuring

1. What are the patterns of use and use dynamics under “routine” conditions?
2. What strategies or combination of strategies (counseling,
communications, mobile technologies) are effective for supporting and bolstering adherence among users?
3. What are feasible approaches to measuring or assessing
adherence under routine service conditions?
VI. Vaginal Ring–Specific Issues
1. How can ring service provision be proactive in supporting
women’s use of the ring, including helping women understand and manage potential expulsions?
2. What are the implications of toileting and hygiene practices
for the use of vaginal rings?
3. What is the feasibility of women (in a given setting) caring for,
washing, and storing the ring in a safe, discreet place?
4. Given that the vaginal ring is not coitally dependent and does
not require daily action, what are the implications for adherence, use, user satisfaction?
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(H, M, L)

Comments

Questions

Timing Priority
(1, 2)

Comments

(H, M, L)

VII. Vaginal Gel–Specific Issues
1. How will the amount of gel provided to users at each visit be
determined? Will initial and resupply visits take place at the
same location? [For specific setting, user groups?]
2. What are the storage implications for gel at the service delivery site? For the user? For logistics and supply systems?
3. What are key messages for users around leakage, lubrication, hygiene, douching, and other vaginal practices?
4. What are the best ways to ensure that clients understand
and correctly use the gel? In pre-filled applicators? In
user-filled paper applicators?
VIII. User Perspectives and Education
1. What do women know about ARV-based prevention? What
are their views about the gel/ring? What are their partners’
views?
2. How can the gel/ring’s partial effectiveness best be
communicated to users?
3. What are the specific requirements for counseling and user
education for gel or ring use? For initial adoption? For ongoing use and resupply?
4. Will gel and rings be explicitly marketed to different user
groups? If so, how will they be identified? If not, how will the
different technologies be provided/described as part of a
package of prevention?
IX. Program Costs
1. What are the anticipated (or likely) product, service, and
program costs? Who is expected to pay these costs?
2. What implications do different program models and
scenarios have for cost?
3. What is the marginal cost of adding the product (gel or ring)
to a given program or system?
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APPENDIX 3
CONSULTATION AGENDA
MONDAY, JUNE 18
9:00 a.m.
9:30 – 10:00

Coffee & continental breakfast (provided)
Meeting Content and Context

10:00 – 11:00

Setting the Stage

What works for HIV prevention for
women? A review of the evidence

Martha Brady, Population
Council
David Stanton, U.S. Agency for
International Development
Co-Chairs: Naomi Rutenberg,
Population Council and
Nono Simelela, The PresidencySouth Africa
Fitih Bicha, Futures Group

What have we learned from other health
Martha Brady, Population
technologies: How do they work for women? Council
11:00 – 11:15
11:15 – 12:30

Discussion, Q and A
Coffee/tea break
ARV-based Prevention Products for Women Chair: Elizabeth Bukusi, Kenya
Medical Research Institute
Overview of clinical trials, product pipelines, Manju Chatani-Gada, AVAC:
and timelines
Global Advocacy for HIV
Prevention
Gels and rings: Where are we?
Joe Romano, Consultant, Bill &
Questions and clarification
Melinda Gates Foundation
Acceptability of rings and gels

12:30 – 1:30
1:30 – 3:00

Discussion, Q and A
Lunch (provided)
Evidence Building

Key outstanding issues with tenofovir gel
WHO guidance: What evidence is needed?

3:00 – 3:15
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Operations research: What it can and cannot do
Coffee/tea break

Cynthia Woodsong, International
Partnership for Microbicides
Chair: Helen Rees, Wits
Reproductive Health and HIV
Research Institute
Tim Farley, Sigma3 Services,
World Health Organization
Consultant
Ian Askew, Population Council/
Kenya

3:15 – 5:15

Review and Generate OR Questions

3:15 – 4:00

Presentation of research topics and questions: Feedback from participants

4:00 – 5:15

Facilitator: Saiqa Mullick,
Population Council/South Africa
Sam Kalibala, Population
Council

Discussion and vetting of broad OR questions for ARV-based prevention products for
women
Facilitators: Sengeziwe Sibeko
and Leila Mansoor
ARV-based gels and rings:
Small groups
Facilitators: Elizabeth Bukusi
• Gel group
and Cynthia Woodsong
• Ring group
Wrap up and instructions for Day Two

5:30 p.m.

Adjourn and reception at
Population Council

TUESDAY, JUNE 19
8:30 a.m.
9:00 –11:00

Coffee & continental breakfast (provided)
Roundup of Questions and Issues

Facilitator: Lori Heise, London
School of Hygiene & Tropical
Medicine

Re-cap of Day One

Elizabeth McGrory, Consultant

Report back: Key questions on gels and
rings

Rapporteurs from groups
Meeting participants

11:00 – 11:15
11:15 – 12:45

Vetting and prioritization
Coffee/tea break
Marrying Research Questions with Research Designs

12:45 – 2:00
2:00 – 3:00
3:00 – 5:00

Group discussion
Lunch (provided)
Wrap Up and Next Steps
David Stanton, Martha Brady
Optional tour of Population Council’s Center CBR Staff
for Biomedical Research (CBR) laboratories
at Rockefeller University (off-site)

Facilitators: Avina Sarna,
Population Council/India and
Ian Askew
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University of Zimbabwe
Harare, Zimbabwe
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